Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Dear Fellow Stockholders,
Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology.
Tevogen has become a recognized name for its business philosophy of social responsibility, patient affordability and cost efficiency. In under five years, we validated our proprietary ExacTcell™ platform, completed successful proof-of-concept clinical trial of the platforms first product, established drug discovery R&D center — currently in the process of establishing our own GMP cell manufacturing facility, expanded corporate infrastructure, built a robust intellectual property portfolio, and established one of the pioneering AI initiatives in the industry — assets of significant value, while maintaining 74% insider equity ownership.
With the successful launch of our proprietary AI-driven PredicTcell™ platform, we've significantly enhanced target discovery efficiency. Strategic partnerships with global technology leaders, such as Microsoft and Databricks, have accelerated our progress. Recent patent filings further secure our intellectual property in AI-driven predictive modeling, positioning us at the forefront of innovation.
Importantly, Tevogen Bio is well capitalized, having access to necessary funding we may require to fully execute our current growth strategy, including the accelerated development of Tevogen.AI. While the sector faces significant challenges, our company continues to grow, underscoring the foundational strength of our company.
We deeply appreciate your continued support as we work toward our vision of transforming healthcare through democratizing access. It feels good to be part of this growth story and am grateful to my colleagues at Tevogen for their exceptional expertise, dedication, and, above all, their compassion for others.
Sincerely,
Ryan Saadi, MD, MPH
Founder and CEO, Tevogen Bio
Recent Announcements
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
Forward-Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
The Province
2 hours ago
- The Province
B.C. researchers now know what's causing billions of sea stars to die
Sea star wasting disease — which causes them to lose their arms and disintegrate into goo — killed off 90 per cent of sunflower sea stars. UBC and Hakai Institute researcher Alyssa Gehman diving in Burke Channel. B.C. researchers have discovered what's causing billions of sea stars to die from a wasting disease. Photo by Bennett Whitnell/Hakai Institute B.C. researchers have unlocked the mystery of why billions of sea stars have died over the past decade from B.C. to Alaska and to Mexico. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors An international study, published Monday in Nature Ecology and Evolution and led by researchers at the University of B.C., the B.C.-based Hakai Institute, and the University of Washington, found that sea star wasting disease is caused by a strain of the bacterium Vibrio pectenicida — one that is related to cholera in humans. Other vibrio species can cause disease in corals and oysters. Sea star wasting disease is considered one of the largest marine epidemics documented, said Alyssa Gehman, senior author of the study and a marine disease ecologist at the Hakai Institute and UBC. Gehman said they estimate about six billion sunflower stars have been lost, and that's just one of 26 species of sea star affected by the disease. Essential reading for hockey fans who eat, sleep, Canucks, repeat. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. UBC and Hakai Institute researcher Alyssa Gehman at Marrowstone marine field station in Washington state. Photo by Kristina Blanchflower/Hakai Inst She said the four-year investigation into the cause was challenging because scientists understand very little about sea stars and what types of pathogens they carry. 'The other big challenge is that right after this disease outbreak, it killed many, many sea stars. And to do the type of work that we did, you need to have animals that don't have the disease, and particularly in sunflower stars, right after the big outbreak there were several years where most had died,' she said. 'We lost 90 per cent of the global population of sunflower stars.' She said sunflower stars, now considered a critically endangered species, used to be abundant in B.C. and could be found in places like the waters off Stanley Park. 'Now there's very little chance you will see them.' This advertisement has not loaded yet, but your article continues below. Photos show sunflower sea stars with wasting disease off Calvert Island. Photo by Grant Callegari/Hakai Institute Photos show sunflower sea stars with wasting disease off Calvert Island. Photo by Grant Callegari/Hakai Institute It's a disease that sounds like something out of a horror film. The sunflower stars start twisting their arms before they deflate, said Gehman. 'They can kind of look like a partially deflated balloon. They'll have wrinkles in their in their skin, you can sometimes get lesions, or sort of like holes in their dermis, where their organs will fall out … and then the next stage is they'll lose an arm,' she said. 'The arm will sort of walk away from the body, it's really horrifying.' Then, they will lose the rest of their arms and begin to disintegrate. 'They sort of end up just being a goopy pile of former sea star. It's horrible,' she said. Sea stars are important to the ocean ecosystem because they are what scientists call a keystone species, keeping nature in balance. This advertisement has not loaded yet, but your article continues below. With the loss of sea stars, one of their main food sources — sea urchins — began to thrive and when that happened urchins munched on kelp forests, decimating some of these important carbon sinks. Kelp forests also provide habitat for an abundance of marine life and protect coastlines from storms. Urchin barren in Hakai Pass. With billions of sea stars dying from a wasting disease, urchins thrive and destroy kelp forests. Photo by Grant Callegari/Hakai Institute The team of scientists discovered the bacteria was the cause by conducting a series of challenge studies, where they collected healthy sea stars and quarantined them for two weeks to ensure they were disease free. Then they would collect some from the wild showing signs of the start of the disease and conduct experiments on how it was transmitted. Vibrio bacterium on the plate. B.C. researchers have discovered the cause of billions of sea stars dying from a wasting disease. Photo by Toby Hall/Hakai Institute Now that scientists have identified the pathogen that causes the wasting disease, they can start to look into where it came from and what's causing it. This advertisement has not loaded yet, but your article continues below. 'It's exciting that we have the opportunity to actually look into that. And there's lots of different ways for us to start to piece together what happened, but at this point, we don't actually know where it came from,' said Gehman. Gehman said they believe there is a link between rising ocean temperatures and wasting disease because other species of vibrio are known to thrive in warmer water. Also, she said there have been 'refuge areas' where the outbreaks haven't been as bad and they are in cooler water, such as B.C.'s Central Coast. 'So if the sea stars are in cooler water, it seems like consequences of the disease is lower,' she said, adding more research is needed to understand how temperature plays a role in the wasting disease. This advertisement has not loaded yet, but your article continues below. The team can also start to look into a cure. Gehman said there has been success with coral in using probiotics to fight off disease so that might be one avenue for exploration with sea stars. She said scientists in the U.S. are breeding and raising sunflower stars in the lab in an attempt to try to find stars that are resistant to this pathogen. 'If we find resistant stars, and we're able to raise them, maybe we can help the populations survive into the future,' she said. Pycnopodia sea stars in Burke Channel. B.C. researchers have discovered what's causing billions of sea stars to die from a wasting disease. Photo by Bennett Whitnell/Hakai Institute The study was also in collaboration with the Nature Conservancy, the Tula Foundation, the U.S. Geological Survey's Western Fisheries Research Center, and the Washington Department of Fish and Wildlife. ticrawford@ Read More
Globe and Mail
2 hours ago
- Globe and Mail
AGL Investors Have Opportunity to Join agilon health, inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President and CEO Steven Sell was stepping down immediately. The Company also withdrew its full-year 2025 financial guidance. Based on this news, shares of Agilon fell by more than 27.2% in after hours trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
